Amy MacQueenAmy graduated from the University of Glasgow in 2009 with an MSci in Molecular and Cellular Biology, which included a year in industry at UCB’s Inflammation Centre of Excellence. She commenced her PhD the same year following a summer placement at GSK, where she worked on PI3K inhibitors in their Respiratory Drug Discovery department. In 2014 Amy received her PhD from the University of Cambridge for her studies on the differential roles for the Class IA PI3K isoforms p110α and p110δ in T cell activation. Amy’s current work at Babraham focuses on the molecular basis underpinning the different roles of these PI3K isoforms in lymphocytes.
Stubbs TM, Bonder MJ, Stark AK
18 1474-760X:68 (2017)
Obesity-Induced Metabolic Stress Leads to Biased Effector Memory CD4(+) T Cell Differentiation via PI3K p110δ-Akt-Mediated Signals.
Mauro C, Smith J, Cucchi D
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Okkenhaug K, Graupera M, Vanhaesebroeck B
Eil R, Vodnala SK, Clever D
537 1476-4687:539-543 (2016)
Lucas CL, Chandra A, Nejentsev S
Nature reviews. Immunology
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI, Chandra A, Bacon CM
The Journal of allergy and clinical immunology
Roychoudhuri R, Clever D, Li P
Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production.
Barbera Betancourt A, Emery JL, Recino A
11 1932-6203:e0146516 (2016)
PI3Kδ promotes CD4(+) T cell interactions with antigen presenting cells by increasing LFA-1 binding to ICAM-1.
Garçon F, Okkenhaug K
Immunology and cell biology
Roychoudhuri R, Eil RL, Clever D
The Journal of clinical investigation
Okkenhaug K, Roychoudhuri R
8 1937-9145:pe3 (2015)
Okkenhaug K, Burger JA
Current topics in microbiology and immunology
393 0070-217X:123-42 (2016)